DK4114826T3 - Krystallinske former af en farmaceutisk forbindelse - Google Patents
Krystallinske former af en farmaceutisk forbindelse Download PDFInfo
- Publication number
- DK4114826T3 DK4114826T3 DK21798287.5T DK21798287T DK4114826T3 DK 4114826 T3 DK4114826 T3 DK 4114826T3 DK 21798287 T DK21798287 T DK 21798287T DK 4114826 T3 DK4114826 T3 DK 4114826T3
- Authority
- DK
- Denmark
- Prior art keywords
- crystalline forms
- pharmaceutical compound
- pharmaceutical
- compound
- crystalline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4114826T3 true DK4114826T3 (da) | 2023-11-13 |
Family
ID=72744696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21798287.5T DK4114826T3 (da) | 2020-10-02 | 2021-10-01 | Krystallinske former af en farmaceutisk forbindelse |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12116344B2 (da) |
| EP (3) | EP3978474A1 (da) |
| JP (2) | JP7809655B2 (da) |
| KR (2) | KR102659466B1 (da) |
| CN (1) | CN116390910A (da) |
| AU (2) | AU2021353055B2 (da) |
| BR (2) | BR112022018020B1 (da) |
| CA (1) | CA3193939C (da) |
| CL (1) | CL2023000943A1 (da) |
| DK (1) | DK4114826T3 (da) |
| ES (1) | ES2964105T3 (da) |
| FI (1) | FI4114826T3 (da) |
| IL (2) | IL316634A (da) |
| MA (1) | MA58885B1 (da) |
| MX (1) | MX2023003618A (da) |
| PE (1) | PE20240138A1 (da) |
| TW (1) | TWI912383B (da) |
| WO (1) | WO2022069709A1 (da) |
| ZA (1) | ZA202310184B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4714497A2 (en) * | 2022-01-10 | 2026-03-25 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| TW202539666A (zh) | 2024-02-01 | 2025-10-16 | 荷蘭商雅捷法羅斯公司 | Gm1神經節苷脂儲積症之治療 |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| WO2026013261A1 (en) * | 2024-07-11 | 2026-01-15 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
| EP4678174A1 (en) * | 2024-07-11 | 2026-01-14 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3461812B1 (en) | 2014-03-27 | 2021-10-13 | Academisch Medisch Centrum | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| EP3314009A2 (en) * | 2015-06-24 | 2018-05-02 | Universiteit Leiden | Glycosylated metabolites |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
- 2021-10-01 TW TW110136766A patent/TWI912383B/zh active
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 JP JP2022577645A patent/JP7809655B2/ja active Active
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4114826T3 (da) | Krystallinske former af en farmaceutisk forbindelse | |
| DK3972960T3 (da) | Krystallinske former af en btk-hæmmer | |
| IL304497A (en) | Crystalline forms of a pyrrolopyridine-aniline compound | |
| IL310264A (en) | Annulated pyridazine compound | |
| DK3880670T3 (da) | Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse | |
| DK4214202T3 (da) | Faste former af en cdk4-hæmmer | |
| DK4313945T3 (da) | Krystallinsk hydrobromidsalt af 5-MeO-DMT | |
| IL286218A (en) | Solid state forms of ripretinib | |
| EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| EP4146799A4 (en) | CRYSTALLINE ANALOGUES OF DIMETHYLTRYPTAMINE | |
| EP4277621A4 (en) | CRYSTALLINE BUFOTENIDINE COMPOUNDS | |
| DK3826982T3 (da) | Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer | |
| IL282454A (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| EP4204551C0 (en) | XYLOGLUCANASE VARIANTS OF FAMILY 44 | |
| DK3749673T3 (da) | Krystallinsk form af bictegravir-natrium | |
| EP4291180A4 (en) | Crystalline 5-methoxy-dipropyl tryptamine compounds | |
| DK3847175T3 (da) | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor | |
| EP4310086A4 (en) | CRYSTALLINE FORM OF A HETEROCYCLIC COMPOUND AS A PROTEIN KINASE INHIBITOR | |
| GB202005114D0 (en) | Crystalline Forms of a Pharmaceutical Compound | |
| DK3459538T3 (da) | Krystallinske salte af et dextroamfetamin-prodrug | |
| DK4132909T3 (da) | Organiske syreadditionssalte af S-pindolol | |
| DK4441028T3 (da) | Salt af S-oxprenolol | |
| EP4169915A4 (en) | CRYSTALLINE FORM OF COMPOUND | |
| EP4479051A4 (en) | (+)-CRYSTALLINE TETRABENAZINE |